X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Boston Properties bought the massive two million-sf class A Carnegie Center two years ago, and recently went into the ground with its first spec office building at the site, the 65,000-sf 302 Carnegie Center. Now, Boston has its first tenant in the building, Akros Pharma, Inc., which signed on the dotted line for 15,500 sf.

Akros is a wholly owned subsidiary of a major Japanese corporation. Based in NYC until now, Akros will use the space as its US headquarters. Motoko Ueno Culp of Redac Inc. repped Akros; John Brandenbergh, Boston’s VP of marketing and leasing, spoke for the owner.

Boston is currently marketing a million feet of build-to-suit space adjacent to Carnegie Center, and expects to break ground on the 140,000-sf 901 Carnegie Center later this year.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

Dig Deeper

 

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.